Janux Therapeutics Files 8-K on Security Holder Vote Matters

TL;DR

Janux Therapeutics is holding a shareholder vote on key matters.

AI Summary

On June 26, 2024, Janux Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The company, incorporated in Delaware with its principal executive offices in San Diego, CA, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates that Janux Therapeutics is proceeding with important decisions requiring shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — The filing is procedural and relates to corporate governance, not immediate financial or operational risks.

Key Numbers

• 001-40475 — SEC File Number (Identifies the company's filing history with the SEC.)
• 82-2289112 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Janux Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices
• June 26, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share JANX Nasdaq Glo

Filing Documents

• janx-20240626.htm (8-K) — 54KB
• 0000950170-24-079059.txt ( ) — 174KB
• janx-20240626.xsd (EX-101.SCH) — 28KB
• janx-20240626_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 26, 2024, Janux Therapeutics, Inc. (the "Company") held the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 29, 2024, the record date for the Annual Meeting, 51,850,667 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number. Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class III directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Vickie Capps 48,034,233 98,744 1,671,776 Jay Lichter, Ph.D. 46,352,481 1,698,166 1,754,106 Jake Simson, Ph.D. 41,538,424 6,589,319 1,677,010 Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 49,801,743 1,682 1,328 –

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. JANUX THERAPEUTICS, INC. Date: June 28, 2024 By: /s/ David Campbell, Ph.D. David Campbell, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR